The pharmaceutical industry is urging the Trump administration and European Union to exclude medical goods from tariff ...
Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...
"Plaintiffs' proposed cash rebate models would have upended the way the 340B Program has operated for more than thirty years ...
Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...
The Trump administration is defending a Biden-era decision to reject drug manufacturer plans that would allow them to discount medicines through a rebate rather than up front under a federal drug ...
Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from the tariff wars, Maggie Fick of ...
Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...
HHS has filed a legal brief urging a federal judge to dismiss lawsuits brought by pharmaceutical companies challenging the agency’s stance on 340B rebate models. Here are four takeaways: ...
Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and U.S. opioid litigation, have agreed to merge ...
The U.K. government proposes raising mandatory drug rebates paid by drug companies to bolster the National Health Service.
During the pandemic, hospitals expanded the amount of 340B revenue they took in by partnering with other pharmacies, and drug makers retaliated by limiting those partnerships.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback